脂联素与视网膜血管性疾病的相关性_Chinese Journal of Ocular Fundus Diseases

Authors：

陶丽妃 , 邱一果 ,  雷博

400016 重庆医科大学附属第一医院眼科眼科学重庆市市级重点实验室重庆市眼科研究所;

Corresponding author：

雷博, Email: bolei99@126.com

Keywords：

视网膜疾病/病理生理学; 脂联素; 脂联素受体; 综述

DOI：

10.3760/cma.j.issn.1005-1015.2015.02.028

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

脂联素(APN)是由脂肪细胞分泌的一种生物活性多肽或蛋白质, 具有增敏胰岛素、抗新生血管、抗炎症反应等生物学特性。近年来研究表明, 血浆APN的变化与糖尿病视网膜病变(DR)、老年性黄斑变性和高血压视网膜病变等常见视网膜疾病相关。血清APN水平降低可能引起微血管病变从而促使DR的发生。局部应用外源性APN可抑制实验性脉络膜新生血管的形成。APN可能通过调节促炎症细胞因子和生长因子的表达来发挥抗新生血管形成的生物学效应。调控APN及其受体可能成为干预视网膜血管性疾病的一种新途径。

Citation： 陶丽妃, 邱一果, 雷博. 脂联素与视网膜血管性疾病的相关性. Chinese Journal of Ocular Fundus Diseases, 2015, 31(2): 202-205. doi: 10.3760/cma.j.issn.1005-1015.2015.02.028 Copy

1.	Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59(5):503-516.
2.	Jahnke K, Korfel A, Komm J, et al. Intraocular lymphoma 2000-2005:results of a retrospective multicentre trial[J]. Graefe's Arch Clin Exp Ophthalmol, 2006, 244(6):663-669.
3.	Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma[J]. Ophthalmology, 1987, 94(12):1631-1639.
4.	Chan CC. Molecular pathology of primary intraocular lymphoma[J]. Trans Am Ophthalmol Soc, 2003, 101:275-292.
5.	Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan[J]. Jpn J Ophthalmol, 2007, 51(1):41-44.
6.	Davis JL. Intraocular lymphoma:a clinical perspective[J]. Eye (Lond), 2013, 27(2):153-162.
7.	Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma:a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16(11):1589-1599.
8.	Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(2):69-72.
9.	Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997[J]. Ann Oncol, 1999, 10(12):1419-1432.
10.	Sauer TC, Meyers SM, Shen D, et al. Primary intraocular (retinal) lymphoma following ocular toxoplasmosis[J]. Retin Cases Brief Rep, 2010, 4(2):160-163.
11.	Chan CC, Shen D, Hackett JJ, et al. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma[J]. Ophthalmology, 2003, 110(2):421-426.
12.	Kimura K, Usui Y, Goto H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J]. Jpn J Ophthalmol, 2012, 56(4):383-389.
13.	周旻, 江睿, 张艳琼, 等.原发性眼内淋巴瘤13例[J].中华眼底病杂志, 2012, 28(3):245-248.
14.	Vollmer L. The diagnosis and management of ocular lymphoma[J]. Optom Vis Sci, 2013, 90(2):56-62.
15.	Grimm SA, Mccannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement:International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71(17):1355-1360.
16.	Aronow ME, Singh AD. The use of imaging in the diagnosis and management of intraocular lymphoma[J]. Int Ophthalmol Clin, 2012, 52(4):199-208.
17.	Fardeau C, Lee CP, Merle-Beral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147(5):886-894.
18.	Egawa M, Mitamura Y, Hayashi Y, et al. Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma[J]. J Ophthalmic Inflamm Infect, 2014, 4(1):7.
19.	Davis JL. Diagnosis of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2004, 12(1):7-16.
20.	Sen HN, Bodaghi B, Hoang PL, et al. Primary intraocular lymphoma:diagnosis and differential diagnosis[J]. Ocul Immunol Inflamm, 2009, 17(3):133-141.
21.	Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma:when, why, how?[J]. Int Ophthalmol Clin, 2014, 54(2):155-171.
22.	Kanavi MR, Soheilian M, Hosseini SB, et al. 25-gauge transconjunctival diagnostic vitrectomy in suspected cases of intraocular lymphoma:a case series and review of the literature[J]. Int J Ophthalmol, 2014, 7(3):577-581.
23.	Wakefield D, Zierhut M. Intraocular lymphoma:more questions than answers[J]. Ocul Immunol Inflamm, 2009, 17(1):6-10.
24.	Coupland SE, Bechrakis NE, Anastassiou G, et al. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome[J]. Graefe's Arch Clin Exp Ophthalmol, 2003, 241(10):860-870.
25.	Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15(81):93-100.
26.	Nasir S, Deangelis LM. Update on the management of primary CNS lymphoma[J]. Oncology (Williston Park), 2000, 14(2):228-234.
27.	Rodriguez EF, Sepah YJ, Jang HS, et al. Cytologic features in vitreous preparations of patients with suspicion of intraocular lymphoma[J]. Diagn Cytopathol, 2014, 42(1):37-44.
28.	Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry[J]. Am J Ophthalmol, 1997, 124(3):362-372.
29.	Wang Y, Shen D, Wang VM, et al. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma[J]. Int J Mol Sci, 2011, 12(9):5684-5697.
30.	Davis JL, Ruiz PJ, Shah M, et al. Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American Ophthalmological Society thesis)[J]. Trans Am Ophthalmol Soc, 2012, 110(12):117-129.
31.	Ohta K, Sano K, Imai H, et al. Cytokine and molecular analyses of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(3):142-147.
32.	Raja H, Snyder MR, Johnston PB, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma. PLoS One, 2013, 8(6):65627.http://dx.plos.org/10.1371/journal.pone.0065627..
33.	Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma[J]. Curr Opin Ophthalmol, 2002, 13(6):411-418.
34.	Teckie S, Yahalom J. Primary intraocular lymphoma:treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55(4):795-801.
35.	Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma[J]. Retina, 2011, 31(3):435-440.
36.	Pe'Er J, Hochberg FH, Foster CS. Clinical review:treatment of vitreoretinal lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(5):299-306.
37.	Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma:implications for external beam radiotherapy[J]. Eye (Lond), 2007, 21(9):1198-1201.
38.	Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma:a retrospective study of 79 cases[J]. Haematologica, 2012, 97(11):1751-1756.
39.	Mason JO, Fischer DH. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma[J]. Ophthalmology, 2003, 110(6):1241-1244.
40.	Itty S, Olson JH, O'Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy[J]. Retina, 2009, 29(3):415-416.
41.	Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience[J]. Br J Ophthalmol, 2008, 92(3):383-388.
42.	Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement[J]. Ophthalmology, 2002, 109(9):1709-1716.
43.	de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma[J]. Br J Ophthalmol, 1999, 83(4):448-451.
44.	Gorovoy I, Prechanond T, Abia M, et al. Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid[J]. Cornea, 2013, 32(8):1171-1173.
45.	Manna S, Augsburger JJ, Correa ZM, et al. Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma:an in vitro study. J Biomech Eng, 2014, 136(2):21018.http://biomechanical.asmedigitalcollection.asme.org/article.aspx?articleid=1789067..
46.	Siegal T. Primary central nervous system. lymphoma:current state of anti-CD20 therapy and appraisal of reported response criteria[J]. J Clin Neurosci, 2014, 21(5):709-715.
47.	Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma[J]. J Clin Oncol, 2001, 19(3):742-749.
48.	Li Z, Mahesh SP, Shen DF, et al.Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma[J]. Cancer Res, 2006, 66(21):10586-10593.
49.	Deangelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma[J]. J Clin Oncol, 1992, 10(4):635-643.

1. Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59(5):503-516.
2. Jahnke K, Korfel A, Komm J, et al. Intraocular lymphoma 2000-2005:results of a retrospective multicentre trial[J]. Graefe's Arch Clin Exp Ophthalmol, 2006, 244(6):663-669.
3. Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma[J]. Ophthalmology, 1987, 94(12):1631-1639.
4. Chan CC. Molecular pathology of primary intraocular lymphoma[J]. Trans Am Ophthalmol Soc, 2003, 101:275-292.
5. Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan[J]. Jpn J Ophthalmol, 2007, 51(1):41-44.
6. Davis JL. Intraocular lymphoma:a clinical perspective[J]. Eye (Lond), 2013, 27(2):153-162.
7. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma:a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16(11):1589-1599.
8. Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(2):69-72.
9. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997[J]. Ann Oncol, 1999, 10(12):1419-1432.
10. Sauer TC, Meyers SM, Shen D, et al. Primary intraocular (retinal) lymphoma following ocular toxoplasmosis[J]. Retin Cases Brief Rep, 2010, 4(2):160-163.
11. Chan CC, Shen D, Hackett JJ, et al. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma[J]. Ophthalmology, 2003, 110(2):421-426.
12. Kimura K, Usui Y, Goto H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J]. Jpn J Ophthalmol, 2012, 56(4):383-389.
13. 周旻, 江睿, 张艳琼, 等.原发性眼内淋巴瘤13例[J].中华眼底病杂志, 2012, 28(3):245-248.
14. Vollmer L. The diagnosis and management of ocular lymphoma[J]. Optom Vis Sci, 2013, 90(2):56-62.
15. Grimm SA, Mccannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement:International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71(17):1355-1360.
16. Aronow ME, Singh AD. The use of imaging in the diagnosis and management of intraocular lymphoma[J]. Int Ophthalmol Clin, 2012, 52(4):199-208.
17. Fardeau C, Lee CP, Merle-Beral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147(5):886-894.
18. Egawa M, Mitamura Y, Hayashi Y, et al. Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma[J]. J Ophthalmic Inflamm Infect, 2014, 4(1):7.
19. Davis JL. Diagnosis of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2004, 12(1):7-16.
20. Sen HN, Bodaghi B, Hoang PL, et al. Primary intraocular lymphoma:diagnosis and differential diagnosis[J]. Ocul Immunol Inflamm, 2009, 17(3):133-141.
21. Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma:when, why, how?[J]. Int Ophthalmol Clin, 2014, 54(2):155-171.
22. Kanavi MR, Soheilian M, Hosseini SB, et al. 25-gauge transconjunctival diagnostic vitrectomy in suspected cases of intraocular lymphoma:a case series and review of the literature[J]. Int J Ophthalmol, 2014, 7(3):577-581.
23. Wakefield D, Zierhut M. Intraocular lymphoma:more questions than answers[J]. Ocul Immunol Inflamm, 2009, 17(1):6-10.
24. Coupland SE, Bechrakis NE, Anastassiou G, et al. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome[J]. Graefe's Arch Clin Exp Ophthalmol, 2003, 241(10):860-870.
25. Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15(81):93-100.
26. Nasir S, Deangelis LM. Update on the management of primary CNS lymphoma[J]. Oncology (Williston Park), 2000, 14(2):228-234.
27. Rodriguez EF, Sepah YJ, Jang HS, et al. Cytologic features in vitreous preparations of patients with suspicion of intraocular lymphoma[J]. Diagn Cytopathol, 2014, 42(1):37-44.
28. Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry[J]. Am J Ophthalmol, 1997, 124(3):362-372.
29. Wang Y, Shen D, Wang VM, et al. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma[J]. Int J Mol Sci, 2011, 12(9):5684-5697.
30. Davis JL, Ruiz PJ, Shah M, et al. Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American Ophthalmological Society thesis)[J]. Trans Am Ophthalmol Soc, 2012, 110(12):117-129.
31. Ohta K, Sano K, Imai H, et al. Cytokine and molecular analyses of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(3):142-147.
32. Raja H, Snyder MR, Johnston PB, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma. PLoS One, 2013, 8(6):65627.http://dx.plos.org/10.1371/journal.pone.0065627..
33. Chan CC, Buggage RR, Nussenblatt RB. Intraocular lymphoma[J]. Curr Opin Ophthalmol, 2002, 13(6):411-418.
34. Teckie S, Yahalom J. Primary intraocular lymphoma:treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55(4):795-801.
35. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma[J]. Retina, 2011, 31(3):435-440.
36. Pe'Er J, Hochberg FH, Foster CS. Clinical review:treatment of vitreoretinal lymphoma[J]. Ocul Immunol Inflamm, 2009, 17(5):299-306.
37. Berenbom A, Davila RM, Lin HS, et al. Treatment outcomes for primary intraocular lymphoma:implications for external beam radiotherapy[J]. Eye (Lond), 2007, 21(9):1198-1201.
38. Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma:a retrospective study of 79 cases[J]. Haematologica, 2012, 97(11):1751-1756.
39. Mason JO, Fischer DH. Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma[J]. Ophthalmology, 2003, 110(6):1241-1244.
40. Itty S, Olson JH, O'Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy[J]. Retina, 2009, 29(3):415-416.
41. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience[J]. Br J Ophthalmol, 2008, 92(3):383-388.
42. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement[J]. Ophthalmology, 2002, 109(9):1709-1716.
43. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma[J]. Br J Ophthalmol, 1999, 83(4):448-451.
44. Gorovoy I, Prechanond T, Abia M, et al. Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid[J]. Cornea, 2013, 32(8):1171-1173.
45. Manna S, Augsburger JJ, Correa ZM, et al. Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma:an in vitro study. J Biomech Eng, 2014, 136(2):21018.http://biomechanical.asmedigitalcollection.asme.org/article.aspx?articleid=1789067..
46. Siegal T. Primary central nervous system. lymphoma:current state of anti-CD20 therapy and appraisal of reported response criteria[J]. J Clin Neurosci, 2014, 21(5):709-715.
47. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma[J]. J Clin Oncol, 2001, 19(3):742-749.
48. Li Z, Mahesh SP, Shen DF, et al.Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma[J]. Cancer Res, 2006, 66(21):10586-10593.
49. Deangelis LM, Yahalom J, Thaler HT, et al. Combined modality therapy for primary CNS lymphoma[J]. J Clin Oncol, 1992, 10(4):635-643.

Previous Article
糖尿病黄斑水肿治疗研究现状与进展
Next Article
眼后节疾病经巩膜给药的影响因素与提高经巩膜给药利用率的途径

Chinese Journal of Ocular Fundus Diseases

脂联素与视网膜血管性疾病的相关性

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content